What are the implications for childhood pneumonia of successfully introducing Hib and pneumococcal vaccines in developing countries?
Scott
J Anthony G
JA
Kenya Medical Research Institute-Wellcome Trust Collaborative Research Programme, Kenya. ascott@ikilifi.net
English
Mike
M
D000900:Anti-Bacterial Agents / Q000191:economics; D019090:Case Management; D002648:Child; D003906:Developing Countries; D018073:Haemophilus Vaccines / Q000627:therapeutic use*; D006291:Health Policy; D006801:Humans; D022242:Pneumococcal Vaccines / Q000627:therapeutic use*; D011014:Pneumonia / Q000145:classification / Q000175:diagnosis / Q000382:microbiology / Q000517:prevention & control*; D018570:Risk Assessment; D014376:Tuberculosis / Q000150:complications; D018074:Vaccines, Conjugate / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D018073:Haemophilus Vaccines; D022242:Pneumococcal Vaccines; D018074:Vaccines, Conjugate